Consolidated statement of changes in equity
In € million |
Equity attributable to equity holders of the parent |
|
||||||||||||||||||||||||
|
Revaluation reserve |
|
||||||||||||||||||||||||
Notes |
Share capital |
Share premiums |
Treasury shares |
Perpetual hybrid bonds |
Retained earnings |
Currency translation differences |
Available-for-sale financial assets |
Cash flow hedges |
Defined benefit pension plan |
Total reserves |
Non-controlling interests |
Total equity |
||||||||||||||
Balance at December 31, 2015 |
|
1,588 |
1,170 |
(230) |
2,188 |
5,720 |
(353) |
(2) |
(28) |
(630) |
7,834 |
245 |
9,668 |
|||||||||||||
Profit (loss) for the year |
|
|
|
|
|
621 |
|
|
|
|
621 |
53 |
674 |
|||||||||||||
Items of other comprehensive income |
|
|
|
|
|
313 |
10 |
23 |
(205) |
141 |
14 |
155 |
||||||||||||||
Comprehensive income |
|
|
|
|
|
621 |
313 |
10 |
23 |
(205) |
762 |
67 |
830 |
|||||||||||||
Cost of stock options |
|
|
|
|
|
9 |
|
|
|
|
9 |
|
9 |
|||||||||||||
Dividends |
|
|
|
|
|
(336) |
|
|
|
|
(336) |
(45) |
(381) |
|||||||||||||
Coupons of perpetual hybrid bonds |
|
|
|
|
|
(84) |
|
|
|
|
(84) |
|
(84) |
|||||||||||||
Acquisition (-) / sale of treasury shares |
|
|
|
(44) |
|
(13) |
|
|
|
|
(57) |
|
(57) |
|||||||||||||
Increase / decrease (-) through changes in ownership interests in subsidiaries that do not result in loss of control |
|
|
|
|
|
(19) |
|
|
|
7 |
(12) |
(17) |
(29) |
|||||||||||||
Balance at December 31, 2016 |
|
1,588 |
1,170 |
(274) |
2,188 |
5,899 |
(39) |
8 |
(5) |
(828) |
8,117 |
250 |
9,956 |
|||||||||||||
Profit (loss) for the year |
|
|
|
|
|
1,061 |
|
|
|
|
1,061 |
56 |
1,116 |
|||||||||||||
Items of other comprehensive income |
|
|
|
|
|
(795) |
(3) |
22 |
128 |
(648) |
(35) |
(684) |
||||||||||||||
Comprehensive income |
|
|
|
|
|
1,061 |
(795) |
(3) |
22 |
128 |
412 |
20 |
433 |
|||||||||||||
Cost of stock options |
|
|
|
|
|
10 |
|
|
|
|
10 |
|
10 |
|||||||||||||
Dividends |
|
|
|
|
|
(363) |
|
|
|
|
(363) |
(41) |
(404) |
|||||||||||||
Coupons of perpetual hybrid bonds |
|
|
|
|
|
(111) |
|
|
|
|
(111) |
|
(111) |
|||||||||||||
Acquisition (-) / sale of treasury shares |
|
|
|
(7) |
|
(7) |
|
|
|
|
(14) |
|
(14) |
|||||||||||||
Increase / decrease (-) through changes in ownership interests in subsidiaries that result in loss of control |
|
|
|
|
|
(34) |
|
|
|
34 |
1 |
(117) |
(116) |
|||||||||||||
Balance at December 31, 2017 |
|
1,588 |
1,170 |
(281) |
2,188 |
6,454 |
(834) |
5 |
16 |
(665) |
8,051 |
113 |
9,752 |
|||||||||||||
The €(117) million reduction in equity relates mainly to non-controlling interests following the completion of the Emerging Biochemicals divestment in 2017.